Drug Trial Radar · NCT01557998
Testing and Linkage to Care for Injecting Drug Users in Kenya
Last checked: Nov 19, 2026Latest source record: Oct 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,449
Actual
Start
May 2012
Primary completion
Apr 30, 2016
Study completion Apr 30, 2018
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NYU Langone Health; Kenya National AIDS & STI Control Programme; National Institute on Drug Abuse (NIDA)
- First posted
- Mar 20, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Testing and Linkage to Care for Injecting Drug Users in Kenya: Interventions for people who inject drugs (PWID) in sub-Saharan African have been almost entirely absent, despite the fact that in countries like Kenya they contribute a growing proportion of incident HIV infections. This study will leverage a historic decision in Kenya to launch needle exchange program (NSP) and related services for this most-at-risk population (MARP). The investigators will use this NSP/MARP platform to seek out PWID, deliver rapid HIV testing, point of care CD4 count and link to ART using peer case managers, and evaluate community viral load impact using a stepped wedge cluster-randomized design. Lessons learned will have important applicability throughout sub-Saharan African. HCV Among PWID in Kenya: A Supplement to the TLC-IDU study: The prevalence of HCV in Kenya, where an increasing number of people who inject drugs (PWID) live and are becoming HIV- as well as HCV-infected, has not been defined. We will establish HCV prevalence among PWID in Nairobi, Western, and Coastal region by adding HCV rapid and confirmatory tests in our parent PWID study (TLC-IDU Kenya); deliver appropriate counseling and treatment options to those eligible; collect HCV treatment adherence data; and disseminate study findings. These data will provide novel and relevant information about HCV and HIV co-infection in Kenya among PWID that will be immediately applicable in terms of public health impact to national and regional HCV testing, counseling, and clinical management policy.
Conditions
- HIV Infection
- HCV Coinfection
Interventions
POC CD4 and Peer Case ManagementBehavioral
HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
HCV+PWIDDrug
Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
Control - No interventionBehavioral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Linkage to care and time to ARTTime frame: Data collection done in 5 waves separated by 6 months
- Community viral load before and after the TLC-IDU initiationTime frame: Data collection done in 5 waves separated by 6 months
- Retention in CareTime frame: Data collection done in 5 waves separated by 6 months
- HCV prevalence determinationTime frame: Data collection done in wave 6 - 6-month-period
- HCV testing and counseling feasibility and acceptability measuresTime frame: Done in wave 6 - 6-month-period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National AIDS/STD Control Programme (NASCOP)
Nairobi, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.